Likewise, Kim et al. [93] recently reported that a biomarker panel comprised of six proteins, including IGFBP2 and IGFBP3, had a high capacity to distinguish patients with intraductal papillary mucinous neoplasm (IPMN) from controls (healthy individuals or with other benign disease). This evidence concerns the gene IGFBP2 and pancreatic intraductal papillary-mucinous neoplasm.